VI. Meta-analysis of calcitonin for the treatment of postmenopausal osteoporosis

Endocrine Reviews

Volumn 23, Issue 4, 2002, Pages 540-551

  Cranney, Ann ^a   Tugwell, Peter ^a   Zytaruk, Nicole ^a   Robinson, Vivian ^a   Weaver, Bruce ^a   Shea, Beverley ^a   Wells, George ^a   Adachi, Jonathan ^a   Waldegger, Lisa ^a   Guyatt, Gordon ^a   Griffith, Lauren ^a   McGowan, Jessie ^a   Willan, Andrew ^a   Rosen, Clifford J ^a   Bilezikian, John P ^a   Black, Dennis M ^a   Favus, Murray J ^a   Fitzpatrick, Lorraine A ^a   Kiel, Douglas P ^a   Marcus, Robert ^a   Orwoll, Eric S ^a   Schnitzer, Thomas J ^a   more..

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN; CALCIUM; SALCATONIN; VITAMIN D;

BONE DENSITY; CLIMACTERIUM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FEMUR NECK; FOREARM; FRACTURE; HEADACHE; HUMAN; INCIDENCE; LUMBAR SPINE; META ANALYSIS; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHINITIS; VERTEBRA FRACTURE;

CALCITONIN; FEMALE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; RANDOMIZED CONTROLLED TRIALS;

EID: 0036679570     PISSN: 0163769X     EISSN: None     Source Type: Journal    
DOI: 10.1210/er.2001-6002     Document Type: Review

References (92)

1. Effect of calcitonin on bone mass and fracture rates
2. Calcitonin for prevention and treatment of osteoporosis
3. Effects of calcitonin on bone quality and osteoblastic function
4. Future horizons for calcitonin: A US perspective
5. Calcitonin
6. Evidence for efficacy of drugs affecting bone metabolism in preventing hip fracture
7. Intranasal salcatonin: A review of its pharmacological properties and role in the management of postmenopausal osteoporosis
8. Neutralizing antibodies against calcitonin
9. Downregulation of calcitonin receptor mRNA expression by calcitonin during human osteoclast-like cell differentiation
10. Osteoporosis: Review of the evidence for prevention, diagnosis and treatment and cost-effectiveness analysis
11. Calcitonin vs. etidronate for the treatment of postmenopausal osteoporosis: A meta-analysis of published clinical trials
12. Effect of calcitonin on vertebral and other fractures
13. Calcitonin-Salmon nasal spray reduces the incidence of new vertebral fractures in postmenopausal women: Three year interim results of the PROOF Study
14. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The prevent recurrence of osteoporotic fractures study
15. Quantitative computed tomography in the assessment of osteoporosis
16. The statistical basis of meta-analysis
17. Treatment of postmenopausal osteoporosis with salmon calcitonin nasal spray: Evaluation by bone mineral content and biochemical patterns
18. Three year calcitonin combination therapy for postmenopausal osteoporosis with crush fractures of the spine
19. Treatment of postmenopausal osteoporosis with continuous daily oral alendronate in comparison with either placebo or intranasal salmon calcitonin
20. Effect of calcitonin and vitamin D on osteoporosis
21. An analgesic effect of synthetic human calcitonin in patients with primary osteoporosis
22. Activity of salmon calcitonin in senile osteoporosis
23. A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis
24. Comparison of the effectiveness of 17-beta-estradiol and calcitonin in women with postmenopausal bone loss
25. Calcifediol and calcitonin in the therapy of rheumatoid arthritis. A short-term controlled study
26. Treatment of postmenopausal osteoporosis with recombinant human growth hormone and salmon calcitonin: A placebo controlled study
27. Rectal salmon calcitonin for the treatment of postmenopausal osteoporosis
28. Effectiveness and safety of medium and long-term elcatonin use in the prevention and treatment of bone mass loss
29. Bone turnover in osteoporosis, effect of calcitonin treatment
30. Long-term calcitonin therapy in postmenopausal osteoporosis
31. Intranasal and intramuscular human calcitonin in female osteoporosis in Paget's disease of bones: A pilot study
32. Long and short term side effects and safety of calcitonin in man: A prospective study
33. Hip fracture in Italy: Epidemiology and preventive efficacy of bone-active drugs
34. Lack of efficacy of nasal spray calcitonin in early postmenopausal women
35. Effect of hormone replacement therapy and calcitonin on bone mass in postmenopausal women
36. Treatment of primary osteoporosis with calcium and salmon calcitonin
37. Lasequenza calcitriolocalcitonina nella terapia dellósteoporosi
38. A 5-year controlled randomized study of prevention of postmenopausal trabecular bone loss with nasal salmon calcitonin and calcium
39. Efficacia clinica di un trattamento con calcitonia di salmone, somministrata per via endonasale per un anno nell'osteoporosi postmenopausale stabilizzata
40. Salmon calcitonin reduces vertebral fracture in postmenopausal crush fracture syndrome
41. A 5-year controlled randomized study of prevention of postmenopausal trabecular bone loss with nasal salmon calcitonin and calcium
42. One year controlled randomized trial of prevention of early postmenopausal bone loss by intranasal calcitonin
43. Long-term treatment of established osteoporosis with intranasal calcitonin
44. Discontinuous calcitonin treatment of established osteoporosis-effects of withdrawal of treatment
45. Long term effect of nasal calcitonin on vertebral and femoral bone mass in early menopause; results of a controlled prospective 3-yr study
46. Salmon-calcitonin nasal spray prevents vertebral fractures in established osteoporosis. Further interim results of the "PROOF" study
47. Salmon calcitonin in the prevention of bone loss at peri-menopause
48. Preventive treatment of cortical bone loss with salmon nasal calcitonin in early postmenopausal women
49. Effects of salmon calcitonin in postmenopausal osteoporosis: A controlled double-blind study
50. Synthetic human calcitonin in postmenopausal osteoporosis: A placebo-controlled, double-blind study
51. Estimated long-term effect of calcitonin treatment in acute osteoporotic spine fractures
52. Acute effect of the intranasal administration of salmon calcitonin in osteoporotic women
53. Studio comparativo randomizzato con carbocalcitonina IM vs. carbocalcitonina spray nasale vs ipriflavone x os nel trattamento dell'osteoporosi postmenopausale
54. Effect of eel calcitonin derivative (elcatonin) in osteoporosis
55. Complementary medical treatment for Colles' fracture: A comparative, randomized, longitudinal study
56. Nasal spray salmon calcitonin in the treatment of senile osteoporosis
57. Effects of salmon calcitonin in postmenopausal osteoporosis: A controlled double-blind clinical study
58. Prevention of postmenopausal bone loss with intranasal calcitonin
59. Treatment of postmenopausal osteoporosis with calcitonin nasal spray evaluated with quantitative computed tomography
60. Calcitonin for the prevention of postmenopausal bone loss
61. Effect of estrogen and calcitonin on vertebral bone density and vertebral height in osteoporotic women
62. Nandrolone decanoate and intranasal calcitonin as therapy in established osteoporosis
63. Effects of nasal administration of calcitonin in oophorectomized women: 2-Year controlled double-blind study
64. Comparison of calcitriol treatment with etidronate-calcitriol and calcitonin-calcitriol combinations in Turkish women with postmenopausal osteoporosis: A prospective study
65. A double blind study of intranasal calcitonin for established postmenopausal osteoporosis
66. Intranasal salmon calcitonin for the prevention and treatment of postmenopausal osteoporosis
67. The effect of different doses of calcitonin on bone mineral density and fracture risk in postmenopausal osteoporosis
68. Salmon calcitonin plus intravaginal estriol: An effective treatment for the menopause
69. Prophylaxis of osteoporosis with calcium, estrogens and/or eelcatonin: Comparative longitudinal study of bone mass
70. Effect of nasal salmon calcitonin on bone remodeling and bone mass in postmenopausal osteoporosis
71. Multicenter comparative study of synthetic salmon calcitonin administered nasally in the treatment of established postmenopausal osteoporosis
72. A double-blind placebo-controlled, dose finding trial of intermittent nasal salmon calcitonin for prevention of postmenopausal lumbar spine loss
73. Prevention of postmenopausal bone loss by rectal calcitonin
74. Total and regional bone mineral content and fracture rate in postmenopausal osteoporosis treated with salmon calcitonin: A prospective study
75. Intranasal calcitonin 50-200 IU does not prevent bone loss in early postmenopausal women
76. Effects of salmon calcitonin suppositories on bone mass and turnover in established osteoporosis
77. Effect of intranasal calcitonin therapy on bone and bone turnover in early postmenopausal women; a dose response study
78. Long term (3 years) prevention of trabecular bone loss with low-dose intermittent nasal salmon calcitonin
79. A clinical trial of the effects of a combination of elcatortin and conjugated estrogens on vertebral bone mass in early postmenopausal women
80. Effects of continuous and cyclic nasal calcitonin administration in ovariectomized women
81. An effective regimen of intranasal salmon calcitonin given in early postmenopausal bone loss
82. Effect of salcalcitonin given intranasally on bone mass and fracture rated in established osteoporosis: A dose-response study
83. Intranasal salmon calcitonin in postmenopausal osteoporosis: Effect of different therapeutic regimens on vertebral and peripheral bone density
84. Postmenopausal osteoporosis: A double-blind placebo-controlled study
85. Effect of different doses of nasal calcitonin on bone mass
86. Dose-effect on bone density and parathyroid function of intranasal salmon calcitonin when administered without calcium in postmenopausal women
87. The role of intranasal salmon calcitonin in the prevention of vertebral and femoral neck bone loss after early menopause
88. Effect of salcatonin given intranasally on early postmenopausal bone loss
89. Nasal calcitonin for treatment of established osteoporosis
90. Comparative effects on bone mineral content of calcium plus salmon calcitonin given in two different regimens in postmenopausal osteoporosis